ARQT's Aroon Indicator triggered a bullish signal on November 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator showed a similar pattern. In 199 of the 222 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
ARQT moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARQT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +7.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in 251 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ARQT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for ARQT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 26 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARQT as a result. In 64 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for ARQT turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.559) is normal, around the industry mean (3.498). ARQT has a moderately high P/E Ratio (116.136) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.435) is also within normal values, averaging (440.869).
INVA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend. In 29 of 39 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INVA as a result. In 43 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.
The Moving Average Convergence Divergence Histogram (MACD) for INVA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 29 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
The 10-day moving average for INVA crossed bearishly below the 50-day moving average on November 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where INVA advanced for three days, in 186 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
INVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 120 of 204 cases where INVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. INVA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.119) is normal, around the industry mean (3.498). P/E Ratio (3.709) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (3.173) is also within normal values, averaging (9.059). Dividend Yield (0.052) settles around the average of (130.981) among similar stocks. P/S Ratio (4.092) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ARQT | INVA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 34 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 85 | 81 | |
SMR RATING 1..100 | 54 | 28 | |
PRICE GROWTH RATING 1..100 | 49 | 70 | |
P/E GROWTH RATING 1..100 | 55 | 96 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INVA's Valuation (83) in the Pharmaceuticals Other industry is in the same range as ARQT (99) in the null industry. This means that INVA’s stock grew similarly to ARQT’s over the last 12 months.
INVA's Profit vs Risk Rating (81) in the Pharmaceuticals Other industry is in the same range as ARQT (85) in the null industry. This means that INVA’s stock grew similarly to ARQT’s over the last 12 months.
INVA's SMR Rating (28) in the Pharmaceuticals Other industry is in the same range as ARQT (54) in the null industry. This means that INVA’s stock grew similarly to ARQT’s over the last 12 months.
ARQT's Price Growth Rating (49) in the null industry is in the same range as INVA (70) in the Pharmaceuticals Other industry. This means that ARQT’s stock grew similarly to INVA’s over the last 12 months.
ARQT's P/E Growth Rating (55) in the null industry is somewhat better than the same rating for INVA (96) in the Pharmaceuticals Other industry. This means that ARQT’s stock grew somewhat faster than INVA’s over the last 12 months.
| ARQT | INVA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 81% |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 75% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 64% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 60% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 57% |
| Advances ODDS (%) | 2 days ago 85% | 14 days ago 63% |
| Declines ODDS (%) | 6 days ago 87% | 3 days ago 64% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 59% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARQT’s FA Score shows that 0 FA rating(s) are green while INVA’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARQT’s TA Score shows that 6 TA indicator(s) are bullish while INVA’s TA Score has 5 bullish TA indicator(s).
ARQT (@Biotechnology) experienced а -14.42% price change this week, while INVA (@Biotechnology) price change was -8.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
ARQT is expected to report earnings on Mar 02, 2027.
INVA is expected to report earnings on Mar 03, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with PTGX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then PTGX could also see price increases.
| Ticker / NAME | Correlation To ARQT | 1D Price Change % | ||
|---|---|---|---|---|
| ARQT | 100% | +4.52% | ||
| PTGX - ARQT | 48% Loosely correlated | +0.26% | ||
| XNCR - ARQT | 46% Loosely correlated | +2.07% | ||
| TRDA - ARQT | 45% Loosely correlated | +11.94% | ||
| PTCT - ARQT | 45% Loosely correlated | -1.37% | ||
| IRON - ARQT | 43% Loosely correlated | +4.16% | ||
More | ||||
A.I.dvisor indicates that over the last year, INVA has been loosely correlated with ARQT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if INVA jumps, then ARQT could also see price increases.
| Ticker / NAME | Correlation To INVA | 1D Price Change % | ||
|---|---|---|---|---|
| INVA | 100% | +0.42% | ||
| ARQT - INVA | 38% Loosely correlated | +4.52% | ||
| ARVN - INVA | 35% Loosely correlated | +2.37% | ||
| DTIL - INVA | 34% Loosely correlated | -1.86% | ||
| LGND - INVA | 31% Poorly correlated | +0.00% | ||
| ATRA - INVA | 31% Poorly correlated | -0.98% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QCML | 15.33 | 0.36 | +2.40% |
| GraniteShares 2x Long QCOM Daily ETF (QCML) | |||
| TSXD | 6.97 | 0.07 | +1.05% |
| Direxion Daily Semiconductors Top 5 Bear 2X ETF (TSXD) | |||
| QQEW | 146.96 | -1.07 | -0.72% |
| First Trust Nasdaq-100 Select Equal Weight ETF (QQEW) | |||
| BKEM | 27.59 | -0.33 | -1.17% |
| BNY Mellon Emerging Markets Equity ETF (BKEM) | |||
| SLVO | 54.67 | -1.96 | -3.45% |
| UBS AG ETRACS Silver Shares Covered Call ETNs due April 21, 2033 ETP 2022-21.04.33 on CS NQ Slv FLS106 Pr (SLVO) | |||